Literature DB >> 16971967

RNA interference for the treatment of cancer.

Lisa N Putral1, Wenyi Gu, Nigel A J McMillan.   

Abstract

RNA interference (RNAi) is the latest new technology in the field of genetic medicine in which specific genes can be turned off, or silenced, so as to affect a therapeutic outcome. It can be highly specific, works in the nanomolar range and is far more effective than the antisense approaches popular 10-15 years ago. Here we review the field and explore the potential role of RNAi in cancer therapy, highlighting recent progress and examining the hurdles that must be overcome before this promising technology is ready for clinical use. (c) 2006 Prous Science. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16971967     DOI： 10.1358/dnp.2006.19.6.985937

Source DB:  PubMed          Journal:  Drug News Perspect        ISSN： 0214-0934


  10 in total

1.  Development of a novel method for formulating stable siRNA-loaded lipid particles for in vivo use.

Authors:  Sherry Y Wu; Lisa N Putral; Mingtao Liang; Hsin-I Chang; Nigel M Davies; Nigel A J McMillan
Journal:  Pharm Res       Date:  2008-11-21       Impact factor: 4.200

2.  E. coli RNase III(E38A) generates discrete-sized products from long dsRNA.

Authors:  Jianping Xiao; Caitlin E Feehery; George Tzertzinis; Claude V Maina
Journal:  RNA       Date:  2009-03-04       Impact factor: 4.942

3.  Small interfering RNA targeting HMGN5 induces apoptosis via modulation of a mitochondrial pathway and Bcl-2 family proteins in prostate cancer cells.

Authors:  Xiao-Yu Zhang; Zhong-Qiang Guo; Shi-Qi Ji; Min Zhang; Ning Jiang; Xue-Song Li; Li-Qun Zhou
Journal:  Asian J Androl       Date:  2012-04-16       Impact factor: 3.285

Review 4.  Lentiviral delivery of short hairpin RNAs.

Authors:  N Manjunath; Haoquan Wu; Sandesh Subramanya; Premlata Shankar
Journal:  Adv Drug Deliv Rev       Date:  2009-03-31       Impact factor: 15.470

5.  Endoribonuclease-prepared short interfering RNAs induce effective and specific inhibition of human immunodeficiency virus type 1 replication.

Authors:  Mireia Gimenez-Barcons; Bonaventura Clotet; Miguel Angel Martinez
Journal:  J Virol       Date:  2007-07-25       Impact factor: 5.103

Review 6.  The role of IGF-1R in pediatric malignancies.

Authors:  Su Young Kim; Jeffrey A Toretsky; Daniel Scher; Lee J Helman
Journal:  Oncologist       Date:  2009-01-06

7.  Down-regulation of uPAR and uPA activates caspase-mediated apoptosis and inhibits the PI3K/AKT pathway.

Authors:  Christopher S Gondi; Neelima Kandhukuri; Dzung H Dinh; Meena Gujrati; Jasti S Rao
Journal:  Int J Oncol       Date:  2007-07       Impact factor: 5.650

8.  Gut indigenous microbiota and epigenetics.

Authors:  Boris Arkadievich Shenderov
Journal:  Microb Ecol Health Dis       Date:  2012-03-28

9.  Enhanced Delivery of Therapeutic siRNA into Glioblastoma Cells Using Dendrimer-Entrapped Gold Nanoparticles Conjugated with β-Cyclodextrin.

Authors:  Jieru Qiu; Lingdan Kong; Xueyan Cao; Aijun Li; Ping Wei; Lu Wang; Serge Mignani; Anne-Marie Caminade; Jean-Pierre Majoral; Xiangyang Shi
Journal:  Nanomaterials (Basel)       Date:  2018-02-27       Impact factor: 5.076

10.  PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells.

Authors:  Wen-Pin Su; Fong-Yu Cheng; Dar-Bin Shieh; Chen-Sheng Yeh; Wu-Chou Su
Journal:  Int J Nanomedicine       Date:  2012-08-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.